Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Xeljanz
Marketing
EMA cracks down on JAK drugs with new limitations
The EMA restrictions follow FDA's policy rolled out last year limiting JAK inhibitors' use behind a TNF blocker in inflammatory diseases.
Angus Liu
Oct 28, 2022 10:20am
Biora, with spin on Xeljanz nearing clinic, posts delivery data
Jul 11, 2022 12:45pm
Docs turning to Bristol's aging Orencia amid JAK safety woes
Apr 13, 2022 9:30am
FDA approves AbbVie's Rinvoq for ulcerative colitis
Mar 17, 2022 11:36am
EMA probes all JAKs after Xeljanz's safety concerns intensify
Feb 11, 2022 3:51pm
Topical combo based on Pfizer and Novartis drugs advances
Jan 25, 2022 8:10am
